Apoptone: Phase I/IIa completed

Harbor completed an open-label, U.S. Phase I/IIa trial evaluating 10-700 mg/day Apoptone in 68

Read the full 147 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE